Debulking, or lowering the tumor load, might provide over all survival benefits for men diagnosed with prostate cancer.
One of the most puzzling questions faced by men with advanced prostate cancer has to do with deciding which drug to take first, Zytiga (abiraterone) or Xtandi (enzalutamide)?
If you have a recurrence of your prostate cancer after primary radiation therapy can a salvage radical prostatectomy (SRP) provide you with any benefits?
Recent research has concluded that for men who are going to use early chemotherapy along with hormone therapy, chemotherapy should be delayed, allowing at least three weeks to pass after starting the hormone therapy before commencing the chemotherapy treatments.
Chemotherapy has a bad reputation because of its side effects. This reputation has contributed to many men deciding not to use it in their treatment protocol. Is this a mistake, we present a small amount of empirical evidence that this can be an error.
Treatment modalities vary for men diagnosed with pathologic lymph node-positive (pN1) prostate cancer. Understanding current treatment patterns and their outcomes can help provide you with insight and direction in your decision-making.